Literature DB >> 17050247

Reconstitution of adaptive and innate immunity following allogeneic hematopoietic stem cell transplantation in humans.

K S Peggs1.   

Abstract

Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment modality for a number of hematologic malignancies, as well as inherited immunodeficiencies and hemoglobinopathies, and may also have a role in selected acquired autoimmune disorders. The complete or near-complete ablation of host immunity and subsequent establishment of donor-derived immunity that is required for successful engraftment and long-term outcomes provide a major obstacle to such transplantation approaches. A delicate balance exists between the need for the reconstituted donor-derived immunity to provide both protection against pathogenic challenges and graft-versus-malignancy activity, and the potentially harmful expansion of alloreactive T-cell clones mediating GvHD. The search for interventions that would allow more rapid and selective reconstitution of beneficial immune specificities continues to be informed by the development of new tools enabling a more precise dissection of the kinetics of reconstituting populations. This review summarizes more recent data on immune reconstitution following allogeneic transplantation in humans.

Entities:  

Mesh:

Year:  2006        PMID: 17050247     DOI: 10.1080/14653240600851938

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  7 in total

1.  Association of Epstein-Barr virus reactivation with the recovery of CD4/CD8 double-negative T lymphocytes after haploidentical hematopoietic stem cell transplantation.

Authors:  Z Bian; J Liu; L-P Xu; Y-J Chang; Y Wang; X-H Zhang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2016-10-31       Impact factor: 5.483

2.  Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age.

Authors:  Emilie Castermans; Muriel Hannon; Jacques Dutrieux; Stéphanie Humblet-Baron; Laurence Seidel; Rémi Cheynier; Evelyne Willems; André Gothot; Jean-François Vanbellinghen; Vincent Geenen; Brenda M Sandmaier; Rainer Storb; Yves Beguin; Frédéric Baron
Journal:  Haematologica       Date:  2010-10-07       Impact factor: 9.941

3.  Allogeneic stem cell transplantation for rheumatic autoimmune diseases.

Authors:  Thomas Hügle; Jacob M van Laar
Journal:  F1000 Med Rep       Date:  2010-03-25

Review 4.  The immunopathology of thymic GVHD.

Authors:  Werner Krenger; Georg A Holländer
Journal:  Semin Immunopathol       Date:  2008-10-31       Impact factor: 9.623

5.  Kinetics of IL-7 and IL-15 levels after allogeneic peripheral blood stem cell transplantation following nonmyeloablative conditioning.

Authors:  Muriel De Bock; Marianne Fillet; Muriel Hannon; Laurence Seidel; Marie-Paule Merville; André Gothot; Yves Beguin; Frédéric Baron
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

6.  The safety and short-term outcomes of allogeneic hematopoietic stem cell transplantation with donor vaccination for COVID-19.

Authors:  Yihan Ding; Yifan Shen; Yi Fan; Jia Chen; Yang Xu; Depei Wu
Journal:  MedComm (2020)       Date:  2022-10-05

Review 7.  Stem cell transplantation for rheumatic autoimmune diseases.

Authors:  Thomas Hügle; Jacob M van Laar
Journal:  Arthritis Res Ther       Date:  2008-10-10       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.